Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in Equatoguinean Children and Older Adults.

Vicente Urbano[1,2], Ally Olotu[1,3], Ali Hamad[1,3], Ali Mtoro[1,3], Mwajuma Chemba[1,3], Stephen R. Manock[1,4], Maximillian Mpina[1,3], Elizabeth Nyakarungu[1,3], Esther Eburi[1,5], Antonio Enrique Ngua Sama Roca[1,5], Martin Eka Ondo Mangue[1,2], Thomas Stabler[1,4], Yonas Abebe[4], Salomón Nguema Owono[4], Matilde Riloha Rivas[4], Chris Schwabe[5], Julie Niemczura de Carvalho[5], Luis Segura[1,5], Wonder Phiri[1,5], Tobias Schindler[6], Elizabeth Saverino[4], Peter F. Billingsley[4], B. Kim Lee Sim[4], Claudia Daubenberger[6,7], Thomas Richie[4], Salim Abdulla[3], Stephen L. Hoffman[4]

1=Equatorial Guinea Malaria Vaccine Initiative; 2=Ministry of Health and Social Welfare; 3=Ifakara Health Institute; 4=Sanaria Inc.; 5=Medical Care Development International; 6=Swiss Tropical and Public Health Institute; 7=University of Basel.

PfSPZ Vaccine is a candidate pre-erythrocytic malaria vaccine composed of aseptic, purified, live (metabolically active), radiation-attenuated, cryopreserved *Plasmodium falciparum* (Pf) NF54 sporozoites (SPZ). In trials in the U.S. and Africa, PfSPZ Vaccine administered by direct venous inoculation (DVI) to young adults proved safe and well-tolerated, and provided durable protection against homologous and heterogenous populations of Pf for at least 24 to 33 weeks. PfSPZ Vaccine has undergone limited testing in children in Tanzania and an ongoing trial in Kenya, but has not previously been tested in older adults. Since the eventual goal is to use PfSPZ Vaccine in mass vaccination programs for malaria elimination in specified geographical areas, it is necessary to test the vaccine in all age groups. As part of a larger randomized, double blind placebo-controlled trial, we evaluated the safety, tolerability, and immunogenicity of PfSPZ Vaccine in 62 healthy malaria-exposed Equatoguinean children and older adults. We randomized 15 adults age 36-65 years to receive 3 doses of $2.7x10^6$ PfSPZ of PfSPZ Vaccine, and 16 children age 11-17 years, 16 children age 6-10 years, and 15 children age 1-5 years to receive 3 doses of $1.8x10^6$ PfSPZ, or placebo at 0, 8 and 16 weeks. A sentinel group of 3 subjects was vaccinated one day prior to the rest of each age cohort. Age de-escalation was done sequentially in children, with safety data evaluated by an external data and safety monitoring board before progressing to the youngest group. Adverse events (AEs) were solicited for 7 days and surveillance for unsolicited AEs done for 28 days after each vaccination. Monitoring for serious AEs was done throughout. Hematologic, renal and hepatic tests were done at baseline, 2 and 14 days after each vaccine dose. Blood samples for immunologic assays were taken prior to and 14 days after each vaccine dose, and at 4 and 20-24 weeks after the final vaccine dose. The vaccine was well-tolerated in all age groups, and DVI was generally straightforward with only mild pain associated with injection. Safety and immunogenicity data will be presented. (ClinicalTrials.gov number, NCT02859350)